| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 26 | 2024 | 1437 | 3.870 |
Why?
|
| Hodgkin Disease | 16 | 2023 | 1384 | 2.460 |
Why?
|
| Lymphoma, B-Cell | 11 | 2023 | 945 | 2.050 |
Why?
|
| Burkitt Lymphoma | 7 | 2022 | 338 | 1.820 |
Why?
|
| Epstein-Barr Virus Infections | 7 | 2022 | 617 | 1.800 |
Why?
|
| Antigens, CD20 | 5 | 2021 | 199 | 1.630 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 7 | 2021 | 168 | 1.500 |
Why?
|
| Mediastinal Neoplasms | 5 | 2020 | 403 | 1.470 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 9 | 2021 | 1408 | 1.450 |
Why?
|
| Proto-Oncogene Proteins c-myc | 7 | 2017 | 998 | 1.440 |
Why?
|
| Heavy Chain Disease | 5 | 2014 | 19 | 1.300 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 4 | 2021 | 125 | 1.290 |
Why?
|
| Flow Cytometry | 12 | 2020 | 5905 | 1.240 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 2 | 2020 | 53 | 1.200 |
Why?
|
| Breast Implants | 6 | 2021 | 414 | 1.150 |
Why?
|
| Lymphoma | 12 | 2024 | 1900 | 1.070 |
Why?
|
| Lymph Nodes | 10 | 2021 | 3473 | 1.030 |
Why?
|
| Immunophenotyping | 14 | 2021 | 1866 | 0.990 |
Why?
|
| Diagnosis, Differential | 31 | 2023 | 13020 | 0.920 |
Why?
|
| Telepathology | 4 | 2012 | 77 | 0.920 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2021 | 1376 | 0.800 |
Why?
|
| Lymphoma, Follicular | 3 | 2022 | 460 | 0.770 |
Why?
|
| Bartonella henselae | 1 | 2021 | 15 | 0.760 |
Why?
|
| Cat-Scratch Disease | 1 | 2021 | 23 | 0.750 |
Why?
|
| Herpesvirus 4, Human | 6 | 2023 | 1082 | 0.670 |
Why?
|
| Inclusion Bodies | 1 | 2020 | 279 | 0.650 |
Why?
|
| Jaundice | 1 | 2019 | 95 | 0.640 |
Why?
|
| Body Fluids | 1 | 2021 | 322 | 0.640 |
Why?
|
| Blood Cells | 1 | 2020 | 309 | 0.610 |
Why?
|
| Immunoproliferative Small Intestinal Disease | 1 | 2018 | 4 | 0.610 |
Why?
|
| Hematologic Neoplasms | 3 | 2022 | 1907 | 0.580 |
Why?
|
| Oligonucleotides | 1 | 2020 | 563 | 0.580 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2020 | 261 | 0.570 |
Why?
|
| Histiocytes | 2 | 2021 | 97 | 0.560 |
Why?
|
| Laboratories | 1 | 2021 | 463 | 0.560 |
Why?
|
| Pathology, Clinical | 5 | 2014 | 377 | 0.550 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2019 | 1560 | 0.540 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 6 | 2021 | 190 | 0.510 |
Why?
|
| Interferon Regulatory Factors | 2 | 2016 | 271 | 0.500 |
Why?
|
| Ethmoid Sinus | 1 | 2015 | 58 | 0.500 |
Why?
|
| Sphenoid Sinus | 1 | 2015 | 101 | 0.480 |
Why?
|
| Immunohistochemistry | 17 | 2023 | 11119 | 0.460 |
Why?
|
| Fibrin | 1 | 2017 | 514 | 0.450 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2016 | 243 | 0.450 |
Why?
|
| Biopsy, Fine-Needle | 6 | 2024 | 1132 | 0.450 |
Why?
|
| Plasmacytoma | 2 | 2014 | 170 | 0.440 |
Why?
|
| Bone Marrow | 6 | 2014 | 2935 | 0.430 |
Why?
|
| Breast Implantation | 3 | 2021 | 225 | 0.430 |
Why?
|
| Cytodiagnosis | 2 | 2021 | 453 | 0.430 |
Why?
|
| Immunoglobulins | 3 | 2016 | 855 | 0.420 |
Why?
|
| Sarcoma, Kaposi | 2 | 2017 | 375 | 0.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2019 | 8664 | 0.420 |
Why?
|
| Gene Rearrangement | 6 | 2021 | 1148 | 0.410 |
Why?
|
| Blood Cell Count | 3 | 2020 | 406 | 0.400 |
Why?
|
| Molluscum Contagiosum | 1 | 2012 | 15 | 0.400 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1794 | 0.400 |
Why?
|
| Humans | 120 | 2024 | 768887 | 0.390 |
Why?
|
| Hypercalcemia | 2 | 2013 | 424 | 0.390 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2011 | 53 | 0.380 |
Why?
|
| Lead Poisoning | 1 | 2014 | 323 | 0.370 |
Why?
|
| alpha-Thalassemia | 1 | 2011 | 53 | 0.370 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 2211 | 0.370 |
Why?
|
| Multiple Myeloma | 4 | 2021 | 5195 | 0.370 |
Why?
|
| Mouth Neoplasms | 1 | 2016 | 597 | 0.370 |
Why?
|
| POEMS Syndrome | 1 | 2010 | 12 | 0.350 |
Why?
|
| DNA-Binding Proteins | 6 | 2024 | 9618 | 0.350 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2010 | 58 | 0.340 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2010 | 91 | 0.340 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2009 | 23 | 0.340 |
Why?
|
| Immunocompromised Host | 2 | 2012 | 865 | 0.330 |
Why?
|
| Bone Marrow Cells | 3 | 2019 | 2414 | 0.330 |
Why?
|
| Carcinoma | 1 | 2021 | 2340 | 0.330 |
Why?
|
| Fractures, Compression | 1 | 2011 | 132 | 0.320 |
Why?
|
| Adult | 53 | 2024 | 223818 | 0.320 |
Why?
|
| Middle Aged | 55 | 2024 | 223740 | 0.320 |
Why?
|
| Tumor Microenvironment | 4 | 2024 | 3951 | 0.310 |
Why?
|
| Macrophages | 2 | 2020 | 5800 | 0.310 |
Why?
|
| B-Lymphocytes | 3 | 2022 | 4794 | 0.300 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 283 | 0.300 |
Why?
|
| Lead | 1 | 2014 | 880 | 0.300 |
Why?
|
| Sacrum | 1 | 2010 | 275 | 0.300 |
Why?
|
| Female | 65 | 2024 | 397464 | 0.300 |
Why?
|
| Male | 59 | 2024 | 365249 | 0.290 |
Why?
|
| Aged | 44 | 2024 | 171790 | 0.290 |
Why?
|
| Genes, myc | 3 | 2019 | 391 | 0.290 |
Why?
|
| Abdominal Pain | 1 | 2014 | 1070 | 0.290 |
Why?
|
| Bone Marrow Examination | 3 | 2019 | 154 | 0.290 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2009 | 259 | 0.290 |
Why?
|
| Thoracic Vertebrae | 1 | 2011 | 614 | 0.270 |
Why?
|
| Fatal Outcome | 4 | 2013 | 1836 | 0.270 |
Why?
|
| Aged, 80 and over | 24 | 2021 | 59738 | 0.270 |
Why?
|
| Radiography | 8 | 2015 | 6991 | 0.270 |
Why?
|
| Translocation, Genetic | 3 | 2021 | 1395 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2019 | 11886 | 0.260 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2015 | 930 | 0.250 |
Why?
|
| Spleen | 4 | 2019 | 2294 | 0.250 |
Why?
|
| Prognosis | 11 | 2024 | 30044 | 0.250 |
Why?
|
| Splenomegaly | 2 | 2011 | 192 | 0.240 |
Why?
|
| Triage | 2 | 2023 | 997 | 0.230 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2017 | 3626 | 0.230 |
Why?
|
| Spinal Fractures | 1 | 2011 | 712 | 0.230 |
Why?
|
| Amyloidosis | 1 | 2011 | 879 | 0.220 |
Why?
|
| Africa, Eastern | 3 | 2012 | 76 | 0.220 |
Why?
|
| Plasma Cells | 5 | 2020 | 599 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 5 | 2021 | 6085 | 0.220 |
Why?
|
| Botswana | 3 | 2022 | 1062 | 0.220 |
Why?
|
| Bleomycin | 2 | 2012 | 493 | 0.220 |
Why?
|
| Stem Cell Transplantation | 3 | 2017 | 1602 | 0.220 |
Why?
|
| Biopsy | 7 | 2023 | 6805 | 0.220 |
Why?
|
| T-Lymphocytes | 3 | 2021 | 10276 | 0.210 |
Why?
|
| Herpesviridae Infections | 3 | 2014 | 269 | 0.210 |
Why?
|
| Hematologic Tests | 2 | 2021 | 239 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3116 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3239 | 0.200 |
Why?
|
| Fever | 2 | 2021 | 1620 | 0.190 |
Why?
|
| Herpesvirus 8, Human | 5 | 2017 | 256 | 0.190 |
Why?
|
| Lumbar Vertebrae | 1 | 2011 | 1889 | 0.190 |
Why?
|
| DNA Mismatch Repair | 1 | 2024 | 432 | 0.190 |
Why?
|
| Flank Pain | 1 | 2021 | 44 | 0.180 |
Why?
|
| Germinal Center | 2 | 2015 | 380 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 6546 | 0.180 |
Why?
|
| Mycoses | 1 | 2024 | 386 | 0.180 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2012 | 682 | 0.180 |
Why?
|
| Erythroblasts | 1 | 2021 | 142 | 0.180 |
Why?
|
| Young Adult | 15 | 2021 | 60110 | 0.170 |
Why?
|
| Immunoglobulin gamma-Chains | 3 | 2014 | 33 | 0.170 |
Why?
|
| Education, Medical | 1 | 2012 | 1742 | 0.170 |
Why?
|
| Recurrence | 6 | 2021 | 8512 | 0.170 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 21187 | 0.170 |
Why?
|
| Treatment Outcome | 17 | 2021 | 65485 | 0.170 |
Why?
|
| Cats | 1 | 2021 | 978 | 0.170 |
Why?
|
| Histocytochemistry | 1 | 2020 | 699 | 0.170 |
Why?
|
| Urine | 1 | 2021 | 362 | 0.170 |
Why?
|
| Waldenstrom Macroglobulinemia | 3 | 2014 | 1077 | 0.160 |
Why?
|
| STAT6 Transcription Factor | 1 | 2019 | 196 | 0.160 |
Why?
|
| Hair Follicle | 1 | 2021 | 219 | 0.160 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2014 | 582 | 0.160 |
Why?
|
| Klebsiella pneumoniae | 1 | 2021 | 253 | 0.160 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 1642 | 0.160 |
Why?
|
| Ki-67 Antigen | 1 | 2021 | 628 | 0.160 |
Why?
|
| Predictive Value of Tests | 10 | 2021 | 15471 | 0.160 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2020 | 283 | 0.150 |
Why?
|
| Neoplasm Staging | 7 | 2021 | 11262 | 0.150 |
Why?
|
| Splenic Neoplasms | 1 | 2008 | 97 | 0.150 |
Why?
|
| Gene Fusion | 1 | 2021 | 357 | 0.150 |
Why?
|
| Africa South of the Sahara | 1 | 2021 | 752 | 0.150 |
Why?
|
| Cell Size | 1 | 2020 | 626 | 0.150 |
Why?
|
| Campylobacter jejuni | 1 | 2018 | 24 | 0.150 |
Why?
|
| Campylobacter Infections | 1 | 2018 | 32 | 0.150 |
Why?
|
| Cytogenetic Analysis | 3 | 2014 | 271 | 0.150 |
Why?
|
| Remote Consultation | 2 | 2012 | 242 | 0.150 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2018 | 79 | 0.150 |
Why?
|
| Treponema pallidum | 1 | 2018 | 48 | 0.150 |
Why?
|
| Tumor Escape | 1 | 2021 | 372 | 0.150 |
Why?
|
| Nausea | 1 | 2021 | 682 | 0.150 |
Why?
|
| Janus Kinase 2 | 1 | 2021 | 560 | 0.150 |
Why?
|
| Neprilysin | 1 | 2021 | 487 | 0.150 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 793 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2010 | 2565 | 0.140 |
Why?
|
| Signal Transduction | 3 | 2017 | 23652 | 0.140 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2011 | 411 | 0.140 |
Why?
|
| Hematology | 1 | 2021 | 243 | 0.140 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2008 | 180 | 0.140 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2008 | 147 | 0.140 |
Why?
|
| Disease-Free Survival | 6 | 2017 | 6856 | 0.140 |
Why?
|
| Anemia | 4 | 2014 | 1516 | 0.140 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2017 | 178 | 0.140 |
Why?
|
| Alopecia | 1 | 2021 | 416 | 0.140 |
Why?
|
| Vincristine | 5 | 2018 | 1040 | 0.140 |
Why?
|
| Diagnostic Errors | 3 | 2018 | 1281 | 0.130 |
Why?
|
| Cholestasis | 1 | 2019 | 385 | 0.130 |
Why?
|
| Chromosome Aberrations | 2 | 2021 | 1780 | 0.130 |
Why?
|
| Remission Induction | 4 | 2021 | 2411 | 0.130 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2017 | 187 | 0.130 |
Why?
|
| Adolescent | 12 | 2019 | 89247 | 0.130 |
Why?
|
| Lymphatic Diseases | 2 | 2013 | 319 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2021 | 708 | 0.130 |
Why?
|
| Blood Coagulation Tests | 1 | 2007 | 270 | 0.130 |
Why?
|
| Lymphoma, T-Cell | 1 | 2008 | 308 | 0.130 |
Why?
|
| Blotting, Southern | 2 | 2011 | 777 | 0.130 |
Why?
|
| Holography | 1 | 2016 | 80 | 0.130 |
Why?
|
| Orbital Pseudotumor | 1 | 2015 | 42 | 0.130 |
Why?
|
| Genes, bcl-2 | 1 | 2015 | 119 | 0.130 |
Why?
|
| In Situ Hybridization | 3 | 2015 | 1904 | 0.120 |
Why?
|
| Erythema | 1 | 2007 | 261 | 0.120 |
Why?
|
| Mouth | 1 | 2018 | 383 | 0.120 |
Why?
|
| Syphilis | 1 | 2018 | 243 | 0.120 |
Why?
|
| Dacryocystitis | 1 | 2015 | 68 | 0.120 |
Why?
|
| Orbital Cellulitis | 1 | 2015 | 33 | 0.120 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2015 | 101 | 0.120 |
Why?
|
| Travel | 1 | 2021 | 805 | 0.120 |
Why?
|
| Hypesthesia | 1 | 2015 | 106 | 0.120 |
Why?
|
| Neoplasm, Residual | 2 | 2017 | 1019 | 0.120 |
Why?
|
| Paraproteinemias | 2 | 2014 | 252 | 0.120 |
Why?
|
| Prednisone | 5 | 2018 | 1567 | 0.120 |
Why?
|
| Thrombophilia | 1 | 2007 | 308 | 0.120 |
Why?
|
| Porphyrias | 1 | 2014 | 57 | 0.110 |
Why?
|
| Retrospective Studies | 17 | 2021 | 81892 | 0.110 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1105 | 0.110 |
Why?
|
| Disease Progression | 5 | 2021 | 13677 | 0.110 |
Why?
|
| Blepharoptosis | 1 | 2015 | 145 | 0.110 |
Why?
|
| Sialadenitis | 1 | 2014 | 45 | 0.110 |
Why?
|
| Diplopia | 1 | 2015 | 217 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2016 | 4413 | 0.110 |
Why?
|
| World Health Organization | 3 | 2022 | 1327 | 0.110 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2003 | 67 | 0.110 |
Why?
|
| Polycythemia | 1 | 2014 | 124 | 0.110 |
Why?
|
| Jaw | 1 | 2013 | 95 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 9264 | 0.110 |
Why?
|
| Transaminases | 1 | 2014 | 199 | 0.110 |
Why?
|
| Sarcoma, Myeloid | 1 | 2013 | 52 | 0.110 |
Why?
|
| Cyclophosphamide | 5 | 2018 | 2227 | 0.110 |
Why?
|
| Skin Diseases | 2 | 2012 | 1085 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2017 | 725 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2014 | 419 | 0.110 |
Why?
|
| Mutation | 7 | 2024 | 30266 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 20776 | 0.100 |
Why?
|
| Urologic Neoplasms | 1 | 2006 | 318 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 2475 | 0.100 |
Why?
|
| Doxorubicin | 5 | 2018 | 2234 | 0.100 |
Why?
|
| Hematuria | 1 | 2013 | 233 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2005 | 559 | 0.100 |
Why?
|
| Receptors, Cell Surface | 2 | 2020 | 2820 | 0.100 |
Why?
|
| Disease Management | 2 | 2020 | 2537 | 0.100 |
Why?
|
| Data Collection | 1 | 2021 | 3322 | 0.100 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2011 | 29 | 0.100 |
Why?
|
| Lupus Nephritis | 1 | 2005 | 327 | 0.100 |
Why?
|
| Immunoglobulin G | 4 | 2018 | 4568 | 0.100 |
Why?
|
| Staining and Labeling | 1 | 2016 | 1081 | 0.100 |
Why?
|
| Orbit | 1 | 2015 | 459 | 0.100 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 839 | 0.100 |
Why?
|
| Time Factors | 5 | 2021 | 40266 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2021 | 24330 | 0.100 |
Why?
|
| Autoimmune Diseases | 2 | 2015 | 2260 | 0.100 |
Why?
|
| Ischemic Attack, Transient | 1 | 2007 | 877 | 0.100 |
Why?
|
| Pleural Effusion | 2 | 2009 | 345 | 0.090 |
Why?
|
| Antigens, CD | 2 | 2020 | 4032 | 0.090 |
Why?
|
| Confusion | 1 | 2013 | 278 | 0.090 |
Why?
|
| Microscopy, Video | 1 | 2012 | 241 | 0.090 |
Why?
|
| Acute Disease | 2 | 2014 | 7245 | 0.090 |
Why?
|
| Gaucher Disease | 1 | 2012 | 110 | 0.090 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 620 | 0.090 |
Why?
|
| Cell Lineage | 1 | 2020 | 2576 | 0.090 |
Why?
|
| Maryland | 1 | 2011 | 278 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 1748 | 0.090 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2001 | 1767 | 0.090 |
Why?
|
| Pancytopenia | 1 | 2012 | 102 | 0.090 |
Why?
|
| Hematopoiesis | 1 | 2020 | 2059 | 0.090 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 384 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 1321 | 0.090 |
Why?
|
| Thalassemia | 1 | 2011 | 267 | 0.090 |
Why?
|
| Hydrocephalus | 1 | 2017 | 770 | 0.090 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2011 | 289 | 0.090 |
Why?
|
| Lymphoid Tissue | 1 | 2012 | 446 | 0.090 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 541 | 0.090 |
Why?
|
| Umbilical Veins | 1 | 2001 | 425 | 0.090 |
Why?
|
| Cell Count | 1 | 2014 | 1833 | 0.090 |
Why?
|
| Nephritis, Interstitial | 1 | 2011 | 158 | 0.090 |
Why?
|
| Codon | 1 | 2011 | 599 | 0.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 1903 | 0.080 |
Why?
|
| Chromosome Deletion | 1 | 2014 | 1390 | 0.080 |
Why?
|
| Antigens, CD19 | 1 | 2013 | 446 | 0.080 |
Why?
|
| Fatigue | 2 | 2014 | 1557 | 0.080 |
Why?
|
| Oncogenes | 1 | 2015 | 1236 | 0.080 |
Why?
|
| Weight Loss | 1 | 2021 | 2720 | 0.080 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2012 | 547 | 0.080 |
Why?
|
| Europe | 1 | 2016 | 3441 | 0.080 |
Why?
|
| Headache | 1 | 2017 | 1263 | 0.080 |
Why?
|
| Varicose Veins | 1 | 2001 | 158 | 0.080 |
Why?
|
| Reed-Sternberg Cells | 1 | 2009 | 78 | 0.080 |
Why?
|
| Bradycardia | 1 | 2011 | 305 | 0.080 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 1483 | 0.080 |
Why?
|
| Escherichia coli | 1 | 2021 | 4212 | 0.080 |
Why?
|
| Data Mining | 1 | 2014 | 563 | 0.080 |
Why?
|
| Observer Variation | 2 | 2012 | 2623 | 0.080 |
Why?
|
| Cardiomegaly | 1 | 2011 | 591 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2019 | 2597 | 0.080 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2015 | 1369 | 0.080 |
Why?
|
| Activins | 1 | 2010 | 211 | 0.080 |
Why?
|
| Surface Properties | 2 | 2021 | 1169 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 664 | 0.080 |
Why?
|
| Brachial Plexus | 1 | 2010 | 173 | 0.080 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 13699 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 1813 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2016 | 5716 | 0.070 |
Why?
|
| Ascites | 1 | 2010 | 338 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 2063 | 0.070 |
Why?
|
| Osteolysis | 1 | 2010 | 274 | 0.070 |
Why?
|
| Karyotyping | 1 | 2010 | 1177 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2017 | 22294 | 0.070 |
Why?
|
| Immunoglobulin Heavy Chains | 3 | 2015 | 648 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 498 | 0.070 |
Why?
|
| Survival Rate | 4 | 2017 | 12873 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2021 | 3590 | 0.070 |
Why?
|
| Antigens, Viral | 1 | 2012 | 996 | 0.070 |
Why?
|
| Neutrophils | 1 | 2020 | 3785 | 0.070 |
Why?
|
| Demyelinating Diseases | 1 | 2010 | 358 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2012 | 2525 | 0.070 |
Why?
|
| Urinary Bladder | 1 | 2013 | 1162 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2013 | 2663 | 0.070 |
Why?
|
| United States | 7 | 2023 | 73180 | 0.070 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2009 | 585 | 0.070 |
Why?
|
| Testicular Neoplasms | 1 | 2013 | 805 | 0.070 |
Why?
|
| Back Pain | 1 | 2011 | 547 | 0.070 |
Why?
|
| HIV Infections | 5 | 2022 | 17589 | 0.070 |
Why?
|
| Bone Diseases, Developmental | 1 | 1997 | 132 | 0.070 |
Why?
|
| Anti-Retroviral Agents | 2 | 2012 | 1794 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2016 | 10115 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 7472 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2014 | 696 | 0.070 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 967 | 0.070 |
Why?
|
| Arteriovenous Anastomosis | 1 | 2005 | 14 | 0.070 |
Why?
|
| Inflammation | 2 | 2017 | 10869 | 0.070 |
Why?
|
| Pre-Eclampsia | 1 | 2005 | 1251 | 0.070 |
Why?
|
| Organ Transplantation | 1 | 2016 | 1178 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 3518 | 0.060 |
Why?
|
| Pilonidal Sinus | 1 | 2005 | 16 | 0.060 |
Why?
|
| Sacrococcygeal Region | 1 | 2005 | 53 | 0.060 |
Why?
|
| Child | 7 | 2021 | 80969 | 0.060 |
Why?
|
| Adenoma | 1 | 2006 | 2164 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 2960 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2021 | 3856 | 0.060 |
Why?
|
| Fetal Diseases | 1 | 2001 | 916 | 0.060 |
Why?
|
| Sclerosis | 2 | 2015 | 212 | 0.060 |
Why?
|
| Visual Acuity | 1 | 2015 | 2714 | 0.060 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 1695 | 0.060 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2009 | 517 | 0.060 |
Why?
|
| Lymphocytes | 2 | 2012 | 2614 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 14751 | 0.060 |
Why?
|
| Logistic Models | 1 | 2020 | 13317 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 8055 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2017 | 9384 | 0.060 |
Why?
|
| Natural Language Processing | 1 | 2014 | 1203 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2014 | 2421 | 0.060 |
Why?
|
| Prosthesis Design | 2 | 2021 | 2126 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2010 | 716 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2012 | 5323 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2022 | 2598 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2017 | 551 | 0.050 |
Why?
|
| Gene Expression | 2 | 2013 | 7602 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2011 | 2871 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2017 | 42684 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 4651 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2010 | 1541 | 0.050 |
Why?
|
| Pregnancy Outcome | 2 | 2001 | 2957 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2008 | 3780 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 3608 | 0.050 |
Why?
|
| Government Agencies | 1 | 2022 | 161 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2010 | 2001 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2005 | 2360 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2022 | 54950 | 0.050 |
Why?
|
| Poly(A)-Binding Protein I | 1 | 2021 | 15 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 2965 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2015 | 36861 | 0.050 |
Why?
|
| Abdomen | 1 | 1997 | 1137 | 0.050 |
Why?
|
| Fungi | 1 | 2024 | 345 | 0.050 |
Why?
|
| Femur | 1 | 1997 | 1320 | 0.050 |
Why?
|
| Immunoglobulin M | 2 | 2012 | 1528 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2011 | 2589 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 39394 | 0.040 |
Why?
|
| Nuclear Proteins | 2 | 2013 | 5803 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 20244 | 0.040 |
Why?
|
| Obesity | 1 | 2022 | 13087 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8745 | 0.040 |
Why?
|
| Kidney | 2 | 2011 | 7057 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2012 | 2192 | 0.040 |
Why?
|
| Lung | 2 | 2014 | 10097 | 0.040 |
Why?
|
| Risk Factors | 3 | 2021 | 74971 | 0.040 |
Why?
|
| Internet | 1 | 2011 | 3112 | 0.040 |
Why?
|
| Genes, T-Cell Receptor gamma | 1 | 2008 | 16 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 1936 | 0.040 |
Why?
|
| Paraproteins | 1 | 2008 | 38 | 0.040 |
Why?
|
| Algorithms | 1 | 2020 | 14199 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2003 | 2931 | 0.040 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2008 | 70 | 0.040 |
Why?
|
| Echocardiography | 1 | 2011 | 5046 | 0.040 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2008 | 72 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2012 | 3626 | 0.040 |
Why?
|
| Boston | 1 | 2011 | 9375 | 0.040 |
Why?
|
| Hospitals, General | 2 | 2014 | 810 | 0.040 |
Why?
|
| Blood Protein Electrophoresis | 1 | 2008 | 65 | 0.040 |
Why?
|
| Pain | 1 | 2013 | 5100 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2014 | 3811 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2011 | 8742 | 0.040 |
Why?
|
| Skin | 1 | 2012 | 4507 | 0.040 |
Why?
|
| Ribosomal Protein S6 | 1 | 2017 | 70 | 0.040 |
Why?
|
| Splenectomy | 1 | 2008 | 392 | 0.030 |
Why?
|
| Ascitic Fluid | 1 | 2007 | 189 | 0.030 |
Why?
|
| Skin Neoplasms | 2 | 2013 | 5864 | 0.030 |
Why?
|
| Bacteriological Techniques | 1 | 2018 | 277 | 0.030 |
Why?
|
| Pregnancy | 4 | 2009 | 30175 | 0.030 |
Why?
|
| Classification | 1 | 2017 | 128 | 0.030 |
Why?
|
| Cytogenetics | 1 | 2017 | 198 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2009 | 6001 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 4980 | 0.030 |
Why?
|
| Heart Failure | 2 | 2011 | 11879 | 0.030 |
Why?
|
| Cerebral Veins | 1 | 2007 | 159 | 0.030 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2006 | 81 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2003 | 5443 | 0.030 |
Why?
|
| Clinical Chemistry Tests | 1 | 2005 | 59 | 0.030 |
Why?
|
| Mass Screening | 1 | 2011 | 5455 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 2 | 2013 | 1625 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 3538 | 0.030 |
Why?
|
| Phototherapy | 1 | 2008 | 368 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 2008 | 350 | 0.030 |
Why?
|
| Thyroiditis | 1 | 2005 | 86 | 0.030 |
Why?
|
| Ifosfamide | 1 | 2015 | 233 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 12563 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 8559 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2022 | 1345 | 0.030 |
Why?
|
| Paraffin | 1 | 2014 | 36 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 2007 | 246 | 0.030 |
Why?
|
| Stroke | 1 | 2007 | 9756 | 0.030 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2006 | 218 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 5342 | 0.030 |
Why?
|
| Pregnancy Proteins | 1 | 2005 | 222 | 0.030 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 11229 | 0.030 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2015 | 148 | 0.030 |
Why?
|
| Databases, Factual | 3 | 2015 | 8095 | 0.030 |
Why?
|
| Urothelium | 1 | 2006 | 276 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2015 | 323 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2015 | 315 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 639 | 0.030 |
Why?
|
| Animals | 4 | 2021 | 169408 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2017 | 8317 | 0.030 |
Why?
|
| Unified Medical Language System | 1 | 2014 | 89 | 0.030 |
Why?
|
| Cytarabine | 1 | 2015 | 697 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2015 | 453 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2014 | 306 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 245 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 4784 | 0.030 |
Why?
|
| Neck | 1 | 2008 | 736 | 0.030 |
Why?
|
| Physician Executives | 1 | 2014 | 140 | 0.030 |
Why?
|
| Brain | 2 | 2011 | 27476 | 0.030 |
Why?
|
| Work | 1 | 2014 | 195 | 0.030 |
Why?
|
| Molecular Biology | 1 | 2017 | 573 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 361 | 0.030 |
Why?
|
| Microspheres | 1 | 2016 | 789 | 0.030 |
Why?
|
| Laboratories, Hospital | 1 | 2014 | 192 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2022 | 1982 | 0.030 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2015 | 240 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 1705 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 859 | 0.030 |
Why?
|
| Acetylation | 1 | 2015 | 1056 | 0.030 |
Why?
|
| Myeloproliferative Disorders | 1 | 2008 | 616 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2013 | 411 | 0.030 |
Why?
|
| Dermis | 1 | 2013 | 203 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2011 | 12174 | 0.020 |
Why?
|
| Death | 1 | 2016 | 683 | 0.020 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 17174 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2012 | 424 | 0.020 |
Why?
|
| Nephrotic Syndrome | 1 | 2005 | 381 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2008 | 1506 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 2126 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2014 | 737 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2005 | 668 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2015 | 1526 | 0.020 |
Why?
|
| Cough | 1 | 2014 | 598 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 1793 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 669 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 2005 | 914 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2013 | 494 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 812 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 488 | 0.020 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2005 | 523 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2012 | 539 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2010 | 144 | 0.020 |
Why?
|
| Necrosis | 1 | 2003 | 1621 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 1469 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2021 | 2350 | 0.020 |
Why?
|
| Methotrexate | 1 | 2015 | 1723 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 9549 | 0.020 |
Why?
|
| Pathology, Surgical | 1 | 2009 | 150 | 0.020 |
Why?
|
| Clone Cells | 1 | 2012 | 1670 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2010 | 440 | 0.020 |
Why?
|
| Syndrome | 1 | 2014 | 3274 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2015 | 1965 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 4835 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 1321 | 0.020 |
Why?
|
| Chest Pain | 1 | 2014 | 1101 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 2574 | 0.020 |
Why?
|
| Neutropenia | 1 | 2012 | 893 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 3554 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 18065 | 0.020 |
Why?
|
| Microscopy | 1 | 2012 | 909 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 1956 | 0.020 |
Why?
|
| Dyspnea | 1 | 2014 | 1352 | 0.020 |
Why?
|
| Placenta | 1 | 2005 | 1721 | 0.020 |
Why?
|
| Congenital Abnormalities | 1 | 2001 | 703 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2830 | 0.020 |
Why?
|
| Sirolimus | 1 | 2012 | 1540 | 0.020 |
Why?
|
| Glomus Tumor | 1 | 2005 | 62 | 0.020 |
Why?
|
| Smooth Muscle Tumor | 1 | 2005 | 65 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 2635 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 4251 | 0.010 |
Why?
|
| Histones | 1 | 2015 | 2603 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2010 | 2931 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 4862 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2012 | 4042 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 1966 | 0.010 |
Why?
|
| Osteoblasts | 1 | 2010 | 1153 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2010 | 1337 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2010 | 11684 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2011 | 5035 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2010 | 3588 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 2009 | 1135 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2784 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 2460 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2012 | 2452 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2012 | 2433 | 0.010 |
Why?
|
| Phenotype | 1 | 2021 | 16735 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2005 | 2171 | 0.010 |
Why?
|
| Protein Binding | 1 | 2015 | 9344 | 0.010 |
Why?
|
| Reference Values | 1 | 2010 | 4941 | 0.010 |
Why?
|
| Alleles | 1 | 2014 | 6901 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 3671 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2010 | 2941 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2013 | 2986 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 2892 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2011 | 4178 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 4528 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 12093 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 26384 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 2431 | 0.010 |
Why?
|
| Genome, Human | 1 | 2012 | 4456 | 0.010 |
Why?
|
| Massachusetts | 1 | 2012 | 8888 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 5544 | 0.010 |
Why?
|
| Gestational Age | 1 | 1997 | 3610 | 0.010 |
Why?
|
| Age Factors | 1 | 2015 | 18454 | 0.010 |
Why?
|
| Sex Factors | 1 | 2012 | 10641 | 0.010 |
Why?
|
| Infant | 2 | 2013 | 36541 | 0.010 |
Why?
|
| Registries | 1 | 2014 | 8384 | 0.010 |
Why?
|
| Comorbidity | 1 | 2012 | 10591 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2009 | 4940 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 12798 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2005 | 26394 | 0.010 |
Why?
|
| Mice | 2 | 2011 | 82074 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2015 | 41800 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 16051 | 0.010 |
Why?
|